Prognostic value of RDW and lactate for short- and long-term mortality in critically ill patients with acute kidney injury.
TL;DR
The combined evaluation of RDW and lactate may improve short- and long-term mortality risk stratification in critically ill patients with acute kidney injury.
Abstract
INTRODUCTION In intensive care units, the strong association between acute kidney injury and mortality has led to a pressing need for simple biomarkers to improve prognostic stratification.
Objective
To evaluate the prognostic value of RDW and lactate for short- and long-term mortality in critically ill patients with acute kidney injury.
Materials And Methods
An analytical study of an open dataset of 2,139 patients with acute kidney injury during their first ICU admission. The main biomarkers were RDW and lactate measured within the first 24 hours, classified into 4 combined categories. Outcomes were 28-day, 90-day, and 1-year mortality. Multivariable logistic regression, Kaplan-Meier survival curves, and Cox adjusted proportional hazards models were used. Results were reported as odds ratios (OR) and hazard ratios (HR) with 95% confidence intervals.
Results
Mortality increased across the combined RDW-lactate categories, with the highest rates observed in patients with both biomarkers elevated: 32.1% at 28 days, 43.6% at 90 days, and 53.0% at 1 year. In adjusted models, both RDW and lactate were independently associated with higher mortality. The RDW × lactate interaction was significant for 90-day mortality (OR 1.13). Cox analysis confirmed a higher risk of 90-day mortality in patients with both biomarkers elevated (HR 1.57). Kaplan-Meier curves showed significant differences in survival (log-rank p < 0.001).
Conclusions
The combined evaluation of RDW and lactate may improve short- and long-term mortality risk stratification in critically ill patients with acute kidney injury.